High-Dose Chemotherapy for Metastatic Breast Cancer
Author Information
Author(s): DA Cameron, J Craig, H Gabral, L Lee, J MacKay, AC Parker, RCF Leonard
Primary Institution: Western General Hospital, Edinburgh, UK
Hypothesis
Can high-dose chemotherapy supported by peripheral blood progenitor cells improve outcomes in women with poor prognosis metastatic breast cancer?
Conclusion
The study found that peripheral blood progenitor cell mobilization and support of high-dose chemotherapy is feasible and can lead to improved survival in patients with metastatic breast cancer.
Supporting Evidence
- PBPC mobilization was successful in 88% of patients.
- The median survival from the start of induction chemotherapy was 15 months.
- There were no treatment-related deaths reported.
Takeaway
Doctors tested a new way to help women with advanced breast cancer live longer by using special blood cells to support strong chemotherapy, and it worked for many of them.
Methodology
The study involved 32 women who received high-dose chemotherapy after an induction regimen, with peripheral blood progenitor cells mobilized using cyclophosphamide and G-CSF.
Potential Biases
There may be selection bias due to the small number of patients and the nature of the treatment regimens.
Limitations
The study had a small sample size and did not determine the optimum drug combination for treatment.
Participant Demographics
The median age of participants was 39 years, with a range from 27 to 55 years.
Statistical Information
P-Value
0.054
Confidence Interval
0-9%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website